<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01198392</url>
  </required_header>
  <id_info>
    <org_study_id>2005L02859</org_study_id>
    <nct_id>NCT01198392</nct_id>
  </id_info>
  <brief_title>Trial of S-1 Plus Cisplatin in Gastric Cancer</brief_title>
  <official_title>A Clinical Trial of S-1 Plus Cisplatin Versus 5-FU Plus Cisplatin in Patients With Unresectable or Advanced Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness and safety of s-1 plus cisplatin
      versus 5-FU plus cisplatin as first-line therapy in the treatment of patients with advanced
      gastric cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, open-label,multicenter study. Patients are randomized to
      one of two treatment arms : S-1 plus cisplatin and 5-FU plus cisplatin.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2008</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>The time from randomization until objective tumor progression or death</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 plus cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks.Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5-Fu plus cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.Number of Cycles: until progression or unacceptable toxicity develops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>s-1 plus cisplatin</intervention_name>
    <description>S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>S-1 plus cisplatin</arm_group_label>
    <other_name>Tegafur,Gimeracil and Oteracil Potassium Capsules</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-Fu plus cisplatin</intervention_name>
    <description>5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.
Number of Cycles: until progression or unacceptable toxicity develops.</description>
    <arm_group_label>5-Fu plus cisplatin</arm_group_label>
    <other_name>5-fluoroura</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenocarcinoma of the stomach with inoperable locally
             advanced or recurrent and/or metastatic disease.

          -  Male or female.

          -  Age 18 -75.

          -  Previous chemotherapy for advanced/metastatic disease (prior adjuvant/neoadjuvant
             therapy is allowed if at least 6 months has elapsed between completion of
             adjuvant/neoadjuvant therapy and enrolment into the study).

          -  Measurable disease, according to the Response Evaluation Criteria in Solid
             Tumours(RECIST)

          -  ECOG Performance status 0, 1 or 2

          -  Haematological, Biochemical and Organ Function: Neutrophil count &gt;2.0 × 10 9/L,
             platelet count &gt; 100 ×10 9/L. Serum bilirubin&lt; 1.5 × upper limit of normal (ULN); or,
             AST or ALT &lt; 2.5 × ULN (or &lt; 5 × ULN in patients with liver metastases); or, alkaline
             phosphatase&lt; 2.5 × ULN (or &gt; 5 × ULN in patients with liver metastases,Creatinine
             clearance &gt; 60 mL/min.

          -  Signed informed consent.

        Exclusion Criteria:

          -  prior adjuvant/neoadjuvant therapy more than two regiments.

          -  Received any investigational drug treatment within 30 days of start of study
             treatment.

          -  Patients with active gastrointestinal bleeding.

          -  Neurological toxicity ≥ grade 2 NCI-CTCAE.

          -  Other malignancy within the last 5 years, except for carcinoma in situ of the cervix,
             or basal cell carcinoma.

          -  History or clinical evidence of brain metastases.

          -  Serious uncontrolled systemic intercurrent illness, e.g. infections or poorly
             controlled diabetes.

          -  Pregnancy women.

          -  Subjects with reproductive potential not willing to use an effective method of
             contraception.

          -  Patients with known active infection with HIV.

          -  Known hypersensitivity to any of the study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>RUIHUA XU, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guan Zhongzhen, Professor</last_name>
    <phone>862087343565</phone>
    <email>guanzhzh@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xu Ruihua, Professor</last_name>
    <phone>862087343228</phone>
    <email>xurh@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Gangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guan Zhongzhen, Professor</last_name>
      <phone>862087343565</phone>
      <email>guanzhzh@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 1, 2010</study_first_submitted>
  <study_first_submitted_qc>September 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 10, 2010</study_first_posted>
  <last_update_submitted>July 22, 2011</last_update_submitted>
  <last_update_submitted_qc>July 22, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Zhongzhen Guan ,Ruihua Xu</name_title>
    <organization>Sun Yat-sen University Cancer Center</organization>
  </responsible_party>
  <keyword>gastric cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

